Newer generations of multi-target CAR and STAb-T immunotherapeutics - NEXT CART Consortium as a cooperative effort to overcome current limitations

Sep 21, 2026

Uploaded by Ivy

Adoptive T cell immunotherapies are positioned as relevant options for cancer patients with relapsed or refractory disease, where traditional treatments no longer provide durable control. Building on advances in chimeric antigen receptor (CAR) T-cell therapy, the work highlights remaining barriers that limit broader use across most cancers. Six Madrid-based research groups established the NEXT Generation CART MAD Consortium to develop and translate novel cell-based strategies for R/R and poor-prognosis cancers, including future-focused directions in CAR signaling, allogeneic products, multi-targeting, and therapy combinations, alongside efforts to refine tumor targeting and immunological synapse efficiency.

LanguageEnglish

CategoryResearch & Report

FormatPDF

Pages9

Reading Time23 min

AccessFree to download

Introduction

Current limitations and clinical context

Future development opportunities and strategies

TYPE Perspective PUBLISHED 08 May 2024 DOI 10.3389/fimmu.2024.1386856 OPEN ACCESS EDITED BY Francisco Martin, University of Granada, Spain REVIEWED BY David John Coe, University of Bristol, United Kingdom Zhitao Ying, Peking University, China *CORRESPONDENCE Beatriz Martn-Antonio [beatriz.antonio@quironsalud.es](beatriz.antonio@quironsalud.es)[ ](beatriz.antonio@quironsalud.es)Bele´n Blanco [bblanco.imas12@h12o.es](bblanco.imas12@h12o.es)[ ](bblanco.imas12@h12o.es)A´frica Gonz´alez-Murillo [africa.gonzalez@salud.madrid.org](africa.gonzalez@salud.madrid.org)[ ](africa.gonzalez@salud.madrid.org)Laura Hidalgo [lhidalgo@isciii.es](lhidalgo@isciii.es)[ ](lhidalgo@isciii.es)Jordi Minguillo´n [jminguillon@ext.cnio.es](jminguillon@ext.cnio.es)[ ](jminguillon@ext.cnio.es)[Gema Pe](Gema Pe)´ rez-Chaco´n [gpchacon@iib.uam.es](gpchacon@iib.uam.es) RECEIVED 16 February 2024 ACCEPTED 23 April 2024 PUBLISHED 08 May 2024 CITATION Martn-Antonio B, Blanco B, Gonz´alez-Murillo A´, Hidalgo L, Minguillo´n J, Pe´ rez-Chaco´n G and Next Generation CART MAD Consortium (2024) Newer generations of multi-target CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations. Front. Immunol. 15:1386856 . doi: 10.3389/fimmu.2024.1386856 COPYRIGHT © 2024 Martn-Antonio, Blanco, Gonz´alez-Murillo, Hidalgo, Minguillo´n, Pe´ rez-Chaco´ n and Next Generation CART MAD Consortium. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. Newer generations of multitarget CAR and STAb-T immunotherapeutics: NEXT CART Consortium as a cooperative effort to overcome current limitations Beatriz Mart ´ın-Antonio 1*, Bel´en Blanco 2*, A´frica Gonz´alez-Murillo 3*, Laura Hidalgo 4*, Jordi Minguillo´ n 5*, Gema P´erez-Chaco´ n 6* and Next Generation CART MAD Consortium 1 Department of Experimental Hematology, Instituto de Investigacio´n Sanitaria-Fundacio´n Jime´nez Diaz (IIS-FJD), Madrid, Spain, 2Cancer Immunotherapy Unit (UNICA), Department of Immunology, Instituto de Investigacio´n Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain, 3 Department of Pediatric Hematology and Oncology, Advanced Therapies Unit, Fundacio´n Investigacio´n Biome´ dica Hospital Infantil Universitario Niño Jesu´s, Madrid, Spain, 4Cellular Biotechnology Unit, Instituto de Salud Carlos III (ISCIII), Madrid, Spain, 5 La Paz Hospital Institute for Health Research (IdiPAZ), Hospital Universitario La Paz. Universidad Auto´noma de Madrid (UAM), Madrid, Spain, 6 Immunity, Immunopathology and Emergent Therapies Group. Instituto de Investigaciones Biomedicas SolsMorreale. CSIC-UAM, Madrid, Spain Adoptive T cellular immunotherapies have emerged as relevant approaches for treating cancer patients who have relapsed or become refractory (R/R) to traditional cancer treatments. Chimeric antigen receptor (CAR) T-cell therapy has improved survival in various hematological malignancies . However, signiﬁcant limitations still impede the widespread adoption of these therapies in most cancers. To advance in this ﬁeld, six research groups have created the“NEXT Generation CART MAD Consortium”(NEXT CART) in Madrid ’s Community, which aims to develop novel cell-based immunotherapies for R/R and poor prognosis cancers. At NEXT CART, various basic and translational research groups and hospitals in Madrid concur to share and synergize their basic expertise in immunotherapy, gene therapy, and immunological synapse, and clinical expertise in pediatric and adult oncology. NEXT CART goal is to develop new cell engineeri

FAQs

What motivates the NEXT Generation CART MAD Consortium?

The consortium was created to address limitations of current T cell-based therapies and advance novel cell-based immunotherapies for relapsed/refractory and poor-prognosis cancers.

What are key future directions mentioned for improving CAR-related therapies?

Planned directions include developing allogeneic products, optimizing CAR signaling domains, combining cellular immunotherapies, applying multi-targeting strategies, and improving tumor-infiltrating lymphocytes (TILs)/TCR therapy.

Why do CAR-T limitations differ across cancers and CAR designs?

Clinical studies indicate that limitations depend on both the specific CAR construct and the malignancy, and they can arise at different treatment stages.

Sep 21, 2026

Uploaded by Ivy